Bayer Pharma R&D Head Tackles Challenge Of Prioritizing Promising Assets
Healthy Pipeline Across All Stages
Nearly a year into the job, research chief Christian Rommel tells Scrip he is impressed with Bayer's arm's length approach to running acquired firms like AskBio and BlueRock and the task ahead is to deliver on the potential they offer, while getting later-stage projects across the approvals finishing line.
You may also be interested in...
The major will use funds from the sale of its male hypogonadism product to invest in future innovation, which is likely to focus on high-risk high-reward cell and gene drug candidates.
The German group is putting another €1.3bn into its Leaps by Bayer investment arm until the end of 2024 to support new companies that are "shifting core paradigms in the sectors of health and agriculture."
Bayer's pharmaceuticals chief Stefan Oelrich says that sales of treatments in the areas of ophthalmology, women’s healthcare and radiology have risen sharply, recovering from the effects of the COVID-19 pandemic.